Technologies That Support Bioprocess Development

⚙️ AI in Biotech – Day 22: Bioprocess Optimization — Making Biotech More Efficient, One Cell at a Time Biotech breakthroughs don’t end in the lab. To bring therapies, enzymes, vaccines, and cell-based products to the world, we need something just as critical: bioprocessing. That’s where AI is stepping up — helping biotech companies fine-tune the way we grow cells, purify proteins, and scale up production without compromising quality. Here’s how AI is transforming bioprocess optimization: 🧫 1. Smarter Cell Culture Management AI can continuously monitor and adjust bioreactor conditions — like pH, temperature, dissolved oxygen, and nutrient supply — in real time. Cytiva’s Ambr® systems integrate AI to predict cell growth and product yield, adjusting media and feeds automatically. MilliporeSigma’s Bio4C® suite uses AI to make cell culture processes more predictable and reproducible. 🧪 2. Faster Process Development Traditionally, optimizing a new process takes weeks or months. AI accelerates this by modeling thousands of variables — and predicting ideal parameters. Novo Nordisk uses AI to reduce time-to-clinic by predicting the best fermentation setups for insulin analogues. Ginkgo Bioworks leverages machine learning to refine microbial fermentation for large-scale biomolecule production. 🧼 3. Predictive Maintenance & Quality Control AI can monitor equipment health and flag anomalies before they cause failures — minimizing downtime and maintaining product integrity. GE Healthcare’s AI-powered bioprocess systems track pump behavior and filtration pressure in real time. Sanofi uses AI-driven dashboards to detect early signs of contamination or batch variability. 💡 4. Sustainable Biomanufacturing By reducing material waste, energy use, and failed batches, AI contributes to a greener and more cost-effective biotech industry. Biogen uses AI to optimize upstream and downstream processing, cutting down on water and raw material usage. 📊 The bottom line? AI isn’t just about discovery — it’s about delivery. Smarter bioprocessing means lower costs, better scalability, fewer batch failures, and faster access to life-saving innovations. Further reads for the Geeks: 🔗Bioprocessing Warms to Artificial Intelligence Bioprocessing Warms to Artificial Intelligence https://lnkd.in/gF8JFUSK 🔗Artificial intelligence technologies in bioprocess: Opportunities and challenges - ScienceDirect https://lnkd.in/gFF2We2E 🔗Artificial Intelligence to Advance Bioprocessing | Frontiers Research Topic https://lnkd.in/g3yf4DiJ 🔗 DeCYPher innovating Bioprocess with microbes and AI https://lnkd.in/gT5MTrm8 🔔Follow me for Day 23: #AIinBiotech #Bioprocessing #Biomanufacturing #SmartLabs #FermentationTech #CellCulture #GreenBiotech #WomenInSTEM #LinkedInSeries

Why P/V (Power per Unit Volume) is a Game Changer in Fermentation Scale-Up Scaling up a fermentation process is one of the biggest challenges in bioprocess engineering. Many rely on tip speed or RPM-based scaling, but these methods often fail to maintain oxygen transfer and mixing efficiency at larger volumes. That’s where P/V (power per unit volume) comes in as a more reliable scale-up parameter. I have personally used P/V-based scale-up many times in my work, and it has consistently given me great success in achieving higher product yield, better oxygen transfer, and smoother scale-ups from lab to production scale. How P/V Helps in Fermentation P/V represents the amount of power input per unit volume of liquid in the fermenter. It directly impacts: ✅ Oxygen Transfer – Essential for aerobic fermentation (higher P/V improves oxygen availability). ✅ Mixing Efficiency – Ensures uniform distribution of nutrients, pH, and temperature. ✅ Heat Dissipation – Prevents overheating, especially in large-scale fermenters. ✅ Scale-Up Consistency – Maintaining constant P/V helps replicate lab-scale performance in production. Case Studies: P/V in Action 🔹 Case Study 1: Scaling Up Recombinant Protein Production in E. coli A biotech company struggled to scale from a 5 L lab reactor to a 10,000 L production bioreactor while maintaining protein yield. Instead of relying on tip speed, they kept P/V constant across scales. As a result, they achieved: ✔ Consistent cell growth and protein expression ✔ Improved oxygen transfer without excessive shear stress ✔ A successful scale-up without costly failures 📖 Reference: • Garcia-Ochoa, F., & Gomez, E. (2009). Bioreactor scale-up and oxygen transfer rate in microbial processes. Biotechnology Advances, 27(2), 153-176. 🔹 Case Study 2: Enzyme Production in Bacillus sp. A company scaling an amylase enzyme fermentation from 50 L to 5,000 L initially faced oxygen limitation and inconsistent enzyme activity. After switching to P/V-based scaling, they: ✔ Maintained oxygen transfer without excessive foaming ✔ Achieved consistent enzyme titers across batches ✔ Reduced variability, improving process stability Key Takeaways ✅ P/V is a powerful tool for scale-up, ensuring uniform oxygen transfer and mixing. ✅ It is more reliable than tip speed or RPM-based methods, especially for aerobic fermentation. ✅ I have personally used P/V for successful scale-ups, achieving better reproducibility and cost savings. Reference 2: https://lnkd.in/g_--q6ye Next time you’re scaling up a fermentation process, think beyond RPM—optimize P/V! Have you used P/V in your scale-up strategy? Let’s discuss in the comments! ⬇️ #BioprocessEngineering #Fermentation #Biotechnology #ScaleUp #Bioprocessing #MicrobialFermentation #Biotech #ProcessOptimization #IndustrialBiotechnology

I still remember 2015 in the lab. Three months. One recombinant protein. Dozens of different host systems, vectors, strains, temperatures - everything you could possibly tweak. Most attempts? Only inclusion bodies. Or worse: NO EXPRESSION. If we hit a 10 % success rate, we celebrated like it was a publication. Fast-forward to 2025: The biggest shift in protein production since recombinant DNA technology isn’t new expression systems or bioreactors. 👉 It’s AI finally understanding what we couldn’t. When AlphaFold2 (2020) arrived, it didn’t just predict structures, it changed how we think about folding, stability, and function. And what came next has transformed expression strategy and design more than any textbook update ever did. Here are a few AI tools that changed the game for me: 🧬 SignalP 6.0: Helps you deciding between periplasmic, secretory, or eukaryotic targeting. 🧫 DeepTMHMM:  Predicts α-helical and β-barrel transmembrane topologies. 🧩 ProteinMPNN:  Designs sequences from backbone structures in seconds. 💫 Rfdiffusion:  Generates new protein backbones nature never imagined. ⚡ ESMFold:  60 × faster than AlphaFold 2 and ideal for high-throughput screening. 🧠 AlphaFold 3: Predicts protein-ligand and complex assemblies. 🔡 CodonTransformer:  AI-driven codon optimization considering tRNA abundance, mRNA folding, and ribosome kinetics. AI is no longer just a “support tool.” It’s rewriting the way we approach protein design and expression. 💬 Which AI tools have changed your workflow? 👇 Drop your favorites below. I’d love to compare notes. If you like insights that blend bench-reality with AI-powered innovation, follow me (Reinhold Horlacher) for more biotech deep dives. #ProteinEngineering #AlphaFold #AIinBiology #ComputationalBiology #ProteinProduction #ExpressionScreening #SyntheticBiology #trenzyme

Sustainability Impacts for Converting to Raman Spectroscopy Inline Monitoring from Traditional Offline Manual Sampling in Small-Scale and Large-Scale Biomanufacturing This study examines the impact of replacing traditional offline manual sampling with inline Raman spectroscopy for monitoring critical bioprocess parameters in both small- and large-scale production. Conventional offline methods for measuring glucose, lactate, viable cell density and osmolality rely heavily on single-use plastics and frequent manual handling, leading to increased waste and carbon emissions. Quantitative analysis shows that integrating inline Raman spectroscopy with predictive modeling can eliminate about 13.36 kg of single-use plastic and prevent 80.17 kg of CO₂ emissions per combined run, with potential for greater annual impact. Raman-enabled process analytical technology enables robust, real-time monitoring, with model performance metrics (R2 and Q2) consistently above 0.79 for key indicators, while also reducing contamination risk by maintaining closed systems. https://lnkd.in/g6iTgzqF #aspenalert #biotech #bioprocess

"We tried 47 different conditions and still can't hit our target titer." Sound familiar? I see this frustration constantly in bioprocess development. Teams running experiment after experiment, changing one variable at a time, hoping something will click. There's a smarter way. When you test pH today, temperature tomorrow, and agitation next week, you're missing the magic that happens between these parameters. What if your optimal pH is 6.8... but only when temperature is above 36°C and dissolved oxygen stays below 40%? You'd never find that sweet spot testing one thing at a time. Design of Experiments doesn't just save time. It reveals the hidden interactions that single-variable testing completely misses. But here's the evolution: forget classical DoE. The smarter approach? Combine DoE with hybrid modeling to leverage all those previous datasets collecting dust in your folders. Instead of starting from scratch every time, use machine learning to identify the most informative experimental conditions before you even step into the lab. This isn't just about running fewer experiments, but it's about running the RIGHT experiments. Here's the game-changing approach: 1. Start with the end in mind → Define your Critical Quality Attributes (what success actually looks like) 2. Mine your historical data → Extract insights from previous experiments and datasets 3. Build hybrid models → Combine mechanistic understanding with machine learning to predict optimal conditions 4. Design targeted experiments → Use model predictions to choose only the most informative experimental conditions 5. Validate and refine → Run strategic experiments to confirm predictions and improve your models The result? Instead of 47 random experiments, you might get your answer in just 8-10 strategic ones. Your previous "failed" experiments suddenly become valuable training data. DoE turns your bioprocess development from art into science. What's been your biggest "aha moment" using DoE? Or are you still stuck in the one-variable-at-a-time trap? #Bioprocessing #DoE #ProcessOptimization #Biotech #DataDriven #Hybrid

From Discovery to Process Control: Why DIA Proteomics is Ready for Biomanufacturing Proteomics has long been a powerhouse in biomedical research, but its potential in biomanufacturing has remained largely untapped. A new preprint manuscript "From Discovery to Process Control: Positioning DIA Proteomics in Biomanufacturing Pipelines," makes a compelling case that this is about to change. The authors benchmark data-independent acquisition (DIA) proteomics across five LC/MS platforms using two biomanufacturing-relevant chassis: E. coli K-12 and Halomonas bluephagenesis. The MS systems utilized span from high-end discovery systems to lower0cost, production-ready instruments. Key Takeaways: - Proteome depth is dependent on the MS system and chromatographic inlet. High end research grade systems quantified about 5,500 proteins, approaching complete coverage of the expressed bacterial proteome. While some MS systems captured fewer protein IDs, actionable insights into core metabolic pathways [critical for process understanding] was still delivered. - Reproducible, quantitative DIA works across platforms. Despite differences in depth, quantitative accuracy and reproducibility were remarkably consistent, exactly what's needed for translation from discovery to routine monitoring. - Biology meets process relevance. Even partial proteome coverage was sufficient to track key pathways like carbon metabolism, demonstrating that proteomics can support troubleshooting, optimization, and Quality-by-Design (QbD) workflows. - A real-world example with Halomonas. By comparing growth on glucose vs. acetate, the study shows how DIA proteomics reveals shifts in carbon flux, directly informing feedstock strategy and metabolic engineering for lower-cost, more sustainable production. Proteomics doesn't have to live exclusively in elite discovery labs. This work outlines a pragmatic, tiered model: deep discovery on high-end systems, followed by targeted or streamlined proteomics on more accessible platforms, bringing protein-level insight directly into development labs and even manufacturing environments. For anyone thinking about next-generation biomanufacturing, this paper is a clear signal: DIA proteomics has potential to become a process control enabler. The full manuscript can be read here: https://lnkd.in/eNkeEpdE #Proteomics, #biomanufacturing, #DIA, #MassSpectrometry, #Biology, #ProcessDevelopment, #QuantitativeProteomics, Evosep Biosystems, Waters Corporation, SCIEX, Thermo Fisher Scientific, Bruker, Future Biomanufacturing Research Hub, University of Liverpool, The University of Manchester Matthew Russell, Philip Brownridge, Joe Windo, Nigel Scrutton, Claire E. Eyers, Perdita Barran

If you run a tissue culture lab, you know oen of the biggest enemy after contamination is variability. For a long time, the industry has relied on "Golden Hands"—the idea that success depends on the subjective intuition of specific technicians. While valuable, that isn't a scalable business model. You can't scale intuition. This is where Artificial Intelligence is finding its foothold. It is shifting the industry from empirical observation to predictive manufacturing. Here is how AI is practically standardizing the grow room: 🔹 Optimization over "Trial & Error" Developing protocols for recalcitrant strains usually involves months of blind A/B testing. Machine Learning models are changing this by analyzing large datasets to predict hormone synergies (Auxin/Cytokinin ratios) in silico. It turns media formulation into a data science problem, drastically reducing R&D cycles. 🔹Automated Quality Control (QC) Human inspection is the bottleneck of high-throughput labs. Computer Vision systems can now monitor explants 24/7, detecting spectral signatures of contamination or hyperhydricity days before they are visible to the human eye. This allows for proactive isolation, preserving the integrity of the batch. 🔹Data-Driven Phenotyping "It looks vigorous" is not a metric you can bank on. AI tools digitize plant growth, instantly quantifying root architecture, leaf surface area, and biomass. This provides the robust, objective data needed to make high-level production decisions. This shift isn’t about removing human expertise. It’s about moving from reactive observation to predictive manufacturing. Question: I’m curious to hear from others in the field: Are you seeing a shift toward these data-driven tools in your workflows yet? 👇 #AgTech #Biotech #PlantScience #TissueCulture #IndustrialBiology #Innovation #Scalability #DeepTech

🔬 Digital Twins in Viral Gene Therapy (VGT) Manufacturing In viral gene therapy manufacturing, the stakes couldn’t be higher. Each batch isn’t just a production run—it represents months of development, millions of dollars in investment, and most importantly, the hope of patients waiting for life-changing therapies. Yet, despite advances in single-use systems, automation, and closed processing, batch failure rates remain a major concern across the industry. The root causes are often multifactorial: variability in raw materials, complex cell culture dynamics, operator handling, equipment inconsistencies, or deviations that cascade into lost production. 💡 This is where Digital Twins can transform the landscape. A digital twin is a virtual replica of your manufacturing process and facility, dynamically updated with real-time data. Imagine a mirror image of your upstream and downstream operations—continuously running in parallel, analyzing every variable, and allowing teams to predict, test, and optimize before making a single physical adjustment on the floor. ✨ The potential impact for VGT manufacturing is immense: 1️⃣ Reducing Batch Failures Digital twins allow process engineers to model “what-if” scenarios—what happens if pH drifts, a parameter spikes, or media quality fluctuates? These insights can flag risks before they impact the bioreactor, helping manufacturers take corrective action proactively. 2️⃣ Accelerating Time to GMP Traditionally, demonstrating process robustness requires multiple engineering and PPQ batches. With digital twins, much of this can be simulated, shortening the experimental cycles. This means faster validation, fewer failed engineering runs, and a smoother path from R&D into GMP readiness. 3️⃣ Enhancing Operational Efficiency From cell growth kinetics to chromatography profiles, digital twins help identify bottlenecks, optimize throughput, and improve yields. Virtual process improvements can be trialed without the cost or downtime of physical runs. 4️⃣ Strengthening Regulatory Readiness Digital twins provide predictive data that can support CMC submissions, helping to justify control strategies, define design space, and improve risk assessments. Regulators are increasingly open to digital tools that provide transparency, consistency, and stronger data-driven justification. 🌍 Why this matters for the future of advanced therapies: As viral vector demand increases, CDMOs & sponsors must navigate shorter timelines, increased cost pressures, and higher regulatory expectations. Digital twins bridge the gap between innovation and compliance. For patients, this means faster access to clinical and commercial products. For companies, it means sustainable operations & reduced cost of goods. 🚨 The challenge? Adoption requires investment in data infrastructure, integration across platforms, and alignment with regulators. But those who embrace it now will be better positioned to lead the next decade of CGT manufacturing.

🚀 5 Breakthrough Advances in Upstream Bioprocessing That Are Reshaping Biomanufacturing 🚀 Biomanufacturing is on the verge of a transformation. With 2024 behind us, I’ve had the privilege of connecting with incredible founders, investors, and innovators across the biomanufacturing value chain—and the energy in this space is electric. ⚡ One of the most exciting trends I’ve observed is the push to rethink bioreactors and bioprocesses. These innovations are critical as the industry shifts beyond clinical and pharma applications, where high-value, low-yield products have traditionally dominated. For non-clinical biomanufacturers, the priority is clear: drive up yield, drive down costs, and scale effectively. Here are five cutting-edge technologies I’ve come across in the last 12–18 months that are set to make waves: 1️⃣ AI/ML-Driven Bioprocess Design Integrating AI/ML into bioprocess design is a game-changer. In silico predictive modeling is enabling higher yields and reducing the number of costly experimental iterations. Startups are tackling this in two ways: Integrated hardware/software solutions: Embedding AI directly into controllers and modeling software. Hardware-agnostic SaaS platforms: Companies like Invert, Algocell, BioRaptor, and Ark are developing software that can integrate with existing infrastructure. Each approach has its strengths—hardware-agnostic platforms, for instance, allow backward compatibility with older systems. 2️⃣ Bioreactor Redesigns The past five years have seen a surge of innovation in bioreactor design. Companies like CULTZYME , Prolific Machines, Stämm and Ever After Foods are completely rethinking the bioreactor and bioprocess to boost yield and cut costs. 3️⃣ Continuous Bioprocessing More contract development and manufacturing organizations (CDMOs) and private biomanufacturers are adopting continuous bioprocessing. Advances in pumps, control systems, monitoring tools, and integrated software are making this possible—and more cost-effective. 📍 Check out Cauldron Ferm in Australia for a great example of what’s happening in this space! 4️⃣ Advances in CIP/SIP Technology Critical process components like Clean-in-Place (CIP) and Sterilize-in-Place (SIP) are evolving. Recent innovations, like Biosphere’s UV sterilization, promise to simplify and optimize these systems. 5️⃣ Downstream Valorization Okay, I’m sneaking in a downstream (DSP) innovation here—but it’s too exciting to leave out! 🌟 Many non-clinical biomanufacturers are exploring ways to diversify their downstream products. Valorizing secondary metabolites and isolating components from spent media are growing priorities. Developing scalable, cost-effective technology for this could unlock significant value, especially for companies pursuing commodity products. What other innovations have I missed? 👋 Hi, I'm James. I'm a strategic advisor and coach to technical founders and managers. #biomanufacturing